BPR1J-097 is primarily researched for its potential in cancer therapy, particularly as an inhibitor of anaplastic lymphoma kinase (ALK). It has shown promise in targeting ALK-positive cancers, such as non-small cell lung cancer (NSCLC), by disrupting the signaling pathways that promote tumor growth. Its application extends to overcoming resistance to existing ALK inhibitors, making it a candidate for second-line or combination therapies. Additionally, studies explore its efficacy in other ALK-driven malignancies, including neuroblastoma and inflammatory myofibroblastic tumors. Further research is ongoing to evaluate its safety, pharmacokinetics, and potential for clinical use.